Elsevier

Clinical Therapeutics

Volume 28, Issue 6, June 2006, Pages 860-871
Clinical Therapeutics

Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels*

https://doi.org/10.1016/j.clinthera.2006.06.010Get rights and content

Background:

High-sensitivity C-reactive protein (hsCRP) and soluble cluster of differentiation 40 ligand (sCD40L) have been established as effective markers of inflammation in predicting the risk for adverse outcomes in patients with acute coronary syndromes (ACSs). Activated platelets secrete certain inflammatory mediators such as P-selectin and sCD40L, which play a role in the pathogenesis of ACSs. Although acetylsalicylic acid (ASA) has been found to be an effective treatment of ACSs, the addition of clopidogrel bisulfate has been found tofurther improve clinical outcomes as a result of additional antiplatelet and anti-inflammatory action. Few data exist concerning the effects of dual antiplatelet therapy on these markers in patients with ACSs.

Objective:

The aim of this study was to assess the effectiveness and clinical significance of clopidogrel administration in patients with ACSs without ST segment elevation treated with ASA.

Methods:

This randomized, single-blind, controlled trial was conducted at the First Department of Cardiology, Hippokration Hospital, Athens, Greece. Inpatients aged ≥21 years with ACSs without ST segment elevation were randomly assigned to 1 of 2 groups: ASA 325 mg/d for 1 week, followed by ASA (100 mg/d) plus clopidogrel (300-mg loading dose followed by 100 mg/d) for 36 weeks (ASA + Clop group) or ASA alone (325 mg/d for 1 week, followed by 75 mg/d for 36 weeks) (ASA group). Levels of serum sCD40L, hsCRP, and P-selectin were determined on admission and at 8 hours, 48 hours, and 6 days of treatment. By means of clinical follow-up, Kaplan-Meier free-of-major adverse cardiovascular events (MACES) plots were used to assess the prevalence of MACES, including cardiovascular-related death, in patients with and without high levels of hsCRP (≥3 mg/L) and sCD40L (≥5 μg/L) for 52 weeks.

Results:

A total of 86 patients were enrolled (71 men, 15 women; mean [SD] age, 68 [3] years; mean [SD] weight, 86 [18] kg; white race, 86 [100%]; 43 patients per group). Both groups had similar initial clinical characteristics and P-selectin levels. Baseline hsCRP and sCD40L levels were correlated with baseline P-selectin levels (hsCRP, r2 = 0.099

Conclusions:

The results of this small study suggest that early activation of platelets, as measured using P-selectin levels, was effectively inhibited by the addition of clopidogrel to a regimen of ASA in the subgroup of patients with ACSs and intense activation of platelets (defined as high hsCRP and sCD40L levels). In patients without high hsCRP and sCD40L levels, the addition of clopidogrel did not have a significant effect on P-selectin levels.

References (26)

  • LibbyP. et al.

    Inflammation and thrombosis: The clot thickens

    Circulation

    (2001)
  • FerreirosE.R. et al.

    Independent prognostic value of elevated C-reactive protein in unstable angina

    Circulation

    (1999)
  • HeeschenC. et al.

    Soluble CD40 ligand in acute coronary syndromes

    N Engl J Med

    (2003)
  • Cited by (29)

    • High Serum sCD40L Levels During the First Week of Malignant Middle Cerebral Artery Infarction and Mortality

      2019, World Neurosurgery
      Citation Excerpt :

      We have excluded patients with diseases that could affect serum sCD40L levels such as sepsis,40 traumatic brain injury,41 and liver diseases,42 and also patients taking statins, for the same reason.28-30 Antiplatelet agents could also affect serum sCD40L levels43-49; however, we have not found significant differences in the antiplatelet treatment rate between survivor and nonsurvivor patients. An association has been found between some genetic polymorphisms and serum sCD40L levels50-54; however, we have not explored genetic polymorphisms and thus, it is possible that genetics could contribute to the difference in serum sCD40L levels between survivor and nonsurvivor patients.

    • Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers

      2018, Journal of Vascular Surgery
      Citation Excerpt :

      Dual antiplatelet therapy consisting of aspirin and clopidogrel in recently symptomatic patients expecting CEA has been associated with a significant reduction in recurrent neurologic events and spontaneous embolization before CEA without significant increase in major perioperative bleeding.28 Another trial analyzing acute coronary syndrome patients showed significant reduction in platelet-released inflammatory mediators in patients with high baseline hs-CRP concentration who were treated with clopidogrel in addition to aspirin.29 In addition to aspirin and clopidogrel, statins might have a crucial role in the prevention of exacerbated inflammatory response, mostly because of their pleiotropic effects.31,32

    • From Atherosclerosis to Acute Coronary Syndromes: The Role of Soluble CD40 Ligand

      2010, Trends in Cardiovascular Medicine
      Citation Excerpt :

      In patients with stable CAD, clopidogrel inhibited the release of sCD40L by platelets, measured at baseline and at 8 weeks (Azar et al. 2006). Moreover, concerning the effects of dual antiplatelet therapy, patients with high levels of high-sensitivity C-reactive protein (CRP) and sCD40L, receiving both acetylsalicylic acid and clopidogrel, exhibited a significantly lower prevalence of major cardiovascular events compared with that in the acetylsalicylic acid group (Vavuranakis et al. 2006). Ticagrelor, similarly with clopidogrel, inhibits platelet function by inhibiting the P2Y12 ADP receptor.

    • The role of platelets CD40 ligand (CD154) in acute coronary syndromes

      2009, Thrombosis Research
      Citation Excerpt :

      On the other hand, the present study found a significant positive correlation between indicators of platelet CD154 (percentage and GMFI) and their congeners of P-selectin among patients with CAD. Our results were in agreement with other previous reports [19,28] and confirmed by logistic regression analyses. Ox-LDL is a more potent pro-atherosclerotic mediator than the native unmodified LDL.

    • Platelet activation in coronary artery disease: Intracardiac vs peripheral venous levels and the effects of angioplasty

      2007, Chest
      Citation Excerpt :

      Indeed, the lower MPC levels after PCI may again reflect our aggressive antiplatelet therapy regime, although we noted morphologic changes within the platelets (larger and more granular) that were suggestive of some activation following PCI. In this study, PCI induced a significant reduction in soluble CD40L levels from both intracardiac and extracardiac samples to a similar degree, which is in contrast to the results of other studies4243 The main difference between our study and previous work was the aggressive use of antiplatelet drugs (which may “damp down” the CD40L response44) and the timing of the sampling. Nonetheless, differences in procedural variables (eg, stenting deployment without prior balloon predilatation or high-pressure stent deployment for a shorter duration) may underline some of the differing-term platelet responses.

    View all citing articles on Scopus
    *

    This article was presented in poster form at the American College of Cardiology Annual Scientific Session 2005, Orlando, Florida, March 6–9, 2005.

    View full text